This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujita, Y. Articles by Tamaki, T. Search for Related Content PubMed PubMed Citation Articles by Fujita, Y. Articles by Tamaki, T.

Transactivation of Fetal Liver Kinase-1/Kinase-Insert Domain-Containing Receptor by Lysophosphatidylcholine Induces Vascular Endothelial Cell Proliferation

Department of Pharmacology (Y.F., M.Y., Y.I., N.A., H.O., Y.K., K.I., T.T.), Graduate School of Medical Sciences, and Department of Clinical Pharmacology (K.T.), Graduate School of Pharmaceutical Sciences, The University of Tokushima Graduate School, Tokushima 770-8503, Japan

Address all correspondence and requests for reprints to: Yoshiko Fujita, Department of Pharmacology, The University of Tokushima Graduate School of Medical Sciences, 3-18-15 Kuramoto, Tokushima 770-8503, Japan. E-mail: fujita56{at}ri.ncvc.go.jp.

Lysophosphatidylcholine (LPC), a major lipid component of oxidized low-density lipoprotein, is a bioactive lipid molecule involved in numerous biological processes including the progression of atherosclerosis. Recently orphan G protein-coupled receptors were identified as high-affinity receptors for LPC. Although several G protein-coupled receptor ligands transactivate receptor tyrosine kinases, LPC-stimulated transactivation of receptor tyrosine kinase has not yet been reported. Here we observed for the first time that LPC treatment of human umbilical vein endothelial cells (HUVECs) induces tyrosyl phosphorylation of vascular endothelial growth factor receptor 2 [fetal liver kinase-1/kinase-insert domain-containing receptor, Flk-1/KDR)]. Flk-1/KDR transactivation by LPC was inhibited by vascular endothelial growth factor receptor tyrosine kinase inhibitors, SU1498 and 4-[(4'-chrolo-2'-fluoro) phenylamino]6,7-dimethoxyquinazoline (VTKi) in immunoprecipitation. Furthermore, we examined the effects of the Src family kinases inhibitors, herbimycin A and 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine (PP2), on LPC-induced Flk-1/KDR transactivation. Results from Western blots, c-Src is involved in LPC-induced Flk-1/KDR transactivation because herbimycin A and PP2 inhibited this transactivation. Kinase-inactive (KI) Src transfection also inhibited LPC-induced Flk-1/KDR transactivation. In addition, results from Western blots, ERK1/2 and Akt, which are downstream effectors of Flk-1/KDR, were also activated by LPC, and this was inhibited by SU1498, VTKi, herbimycin A, PP2, and KI Src transfection in HUVECs. LPC-induced stimulation of HUVEC proliferation was shown to be secondary to transactivation because it was suppressed by SU1498, VTKi, herbimycin A, PP2, and KI Src transfection in dimethylthiazoldiphenyltetra-zoliumbromide assay. These findings suggest that LPC-induced Flk-1/KDR transactivation via c-Src may have important implications for the progression of atherosclerosis.

This article has been cited by other articles:

				F. Surrel, I. Jemel, E. Boilard, J. G. Bollinger, C. Payre, C. M. Mounier, K. A. Talvinen, V. J. O. Laine, T. J. Nevalainen, M. H. Gelb, et al. Group X Phospholipase A2 Stimulates the Proliferation of Colon Cancer Cells by Producing Various Lipid Mediators Mol. Pharmacol., October 1, 2009; 76(4): 778 - 790. [Abstract] [Full Text] [PDF]

				A. Linkous, L. Geng, A. Lyshchik, D. E. Hallahan, and E. M. Yazlovitskaya Cytosolic Phospholipase A2: Targeting Cancer through the Tumor Vasculature Clin. Cancer Res., March 1, 2009; 15(5): 1635 - 1644. [Abstract] [Full Text] [PDF]

				Y. Greenberg, M. King, W. B. Kiosses, K. Ewalt, X. Yang, P. Schimmel, J. S. Reader, and E. Tzima The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells FASEB J, May 1, 2008; 22(5): 1597 - 1605. [Abstract] [Full Text] [PDF]

				M. L. Petreaca, M. Yao, Y. Liu, K. DeFea, and M. Martins-Green Transactivation of Vascular Endothelial Growth Factor Receptor-2 by Interleukin-8 (IL-8/CXCL8) Is Required for IL-8/CXCL8-induced Endothelial Permeability Mol. Biol. Cell, December 1, 2007; 18(12): 5014 - 5023. [Abstract] [Full Text] [PDF]

				A. Zimman, K. P. Mouillesseaux, T. Le, N. M. Gharavi, A. Ryvkin, T. G. Graeber, T. T. Chen, A. D. Watson, and J. A. Berliner Vascular Endothelial Growth Factor Receptor 2 Plays a Role in the Activation of Aortic Endothelial Cells by Oxidized Phospholipids Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 332 - 338. [Abstract] [Full Text] [PDF]

				D.-Y. Xuan, X. Li, Z.-H. Deng, H.-L. Zhang, P.-x. Feng, X.-Y. Duan, and Y. Jin Identification and Characterization of a Novel Gene, Mcpr1, and Its Possible Function in the Proliferation of Embryonic Palatal Mesenchymal Cells J. Biol. Chem., November 10, 2006; 281(45): 33997 - 34008. [Abstract] [Full Text] [PDF]